^
Association details:
| Biomarker: | MGMT unmethylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Libtayo (cemiplimab-rwlc) (PD1 inhibitor) + INO-5401 (Cytotoxic T lymphocyte stimulant, PSMA inhibitor, Wilms tumor 1 inhibitor, hTERT inhibitor) + rocakinogene sifuplasmid (INO-9012) (IL-12 stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma
Published date:
05/26/2022
Excerpt:
This is a phase I/II, single arm, two cohort (A: unmethylated MGMT and B: methylated MGMT) study. Median OS durations in Cohorts A and B were 17.9 months (95% CI 14.5-19.8) and 32.5 months (95% CI 18.4-not reached), respectively. Pre-treatment gene expression signatures in MGMT-unmethylated patients were statistically associated with OS18.
DOI:
10.1200/JCO.2022.40.16_suppl.2004
Trial ID:
Source:
Title:
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting
Published date:
11/20/2020
Excerpt:
The study demonstrated that INO-5401 + INO-9012 with Libtayo, radiation (RT) and temozolomide (TMZ) are tolerable...Survival data at 18 months showed that 70% (14/20) of MGMT promoter methylated GBM patients were alive, and 50% (16/32) of MGMT promoter unmethylated patients, which are the more difficult to treat group, were alive after 18 months.
Secondary therapy:
temozolomide
